New triple therapy aims to shrink rectal tumors and avoid surgery
NCT ID NCT07175636
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new approach for people with locally advanced rectal cancer that is not responding well to standard immunotherapy. Participants will receive short-course radiation, followed by an experimental drug (QL1706) that boosts the immune system, plus chemotherapy. The goal is to see if this combination can completely eliminate the tumor before surgery, and possibly allow some patients to avoid surgery altogether.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL1706 (an experimental antibody targeting PD-1 and CTLA-4) combined with mFOLFOX6 chemotherapy and short-course radiotherapy
- What this could lead to
- If successful, this combination could offer a more effective way to shrink tumors before surgery, potentially allowing some patients to avoid surgery altogether and preserve their rectum.
- What could go wrong
- This is an early-phase trial with only 66 participants, so results may not apply to everyone. The experimental drug QL1706 is new, and combining it with radiation and chemotherapy could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy aims to shrink rectal tumors before Surgery—Could spare some patients the knife
- New combo therapy aims to spare organs in High-Risk rectal cancer
- Blood test could revolutionize rectal cancer monitoring
- New drug duo takes on tough rectal cancer
- Blood test may predict rectal cancer treatment success
- New drug combo may help avoid surgery in rectal cancer patients